Abstract
Calprotectin, a protein composed by two subunits of 8 and 14 kD respectively, is released by neutrophils in the biological fluids under inflammatory states. For instance, detection of calprotectin in faeces represents a diagnostic tool in the case of inflammatory bowel disease. Quite interestingly, calprotectin is increased in the stool of healthy newborns from day three up to day thirty and, physiologically, this increase may be interpreted as a defense mechanism against yeast and fungi. Therapeutic attempts at inhibiting the deleterious effect of calprotectin have been experimentally made by using lycoricinidol. This natural compound is able to hamper the calprotectin-induced apoptosis on the one hand. On the other hand, the same compound plays a prophylactic role in the course of experimental arthritis in rats.
Keywords: Calprotectin, inflammatory bowel disease, newborns, lycoricidinol
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Does Calprotectin Represent a Regulatory Factor in Host Defense or a Drug Target in Inflammatory Disease?
Volume: 7 Issue: 1
Author(s): M. E. Baldassarre, M. A. Altomare, M. Fanelli, D. Carbone, G. Di Bitonto, A. Mautone and N. Laforgia
Affiliation:
Keywords: Calprotectin, inflammatory bowel disease, newborns, lycoricidinol
Abstract: Calprotectin, a protein composed by two subunits of 8 and 14 kD respectively, is released by neutrophils in the biological fluids under inflammatory states. For instance, detection of calprotectin in faeces represents a diagnostic tool in the case of inflammatory bowel disease. Quite interestingly, calprotectin is increased in the stool of healthy newborns from day three up to day thirty and, physiologically, this increase may be interpreted as a defense mechanism against yeast and fungi. Therapeutic attempts at inhibiting the deleterious effect of calprotectin have been experimentally made by using lycoricinidol. This natural compound is able to hamper the calprotectin-induced apoptosis on the one hand. On the other hand, the same compound plays a prophylactic role in the course of experimental arthritis in rats.
Export Options
About this article
Cite this article as:
Baldassarre E. M., Altomare A. M., Fanelli M., Carbone D., Di Bitonto G., Mautone A. and Laforgia N., Does Calprotectin Represent a Regulatory Factor in Host Defense or a Drug Target in Inflammatory Disease?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187153007780059441
DOI https://dx.doi.org/10.2174/187153007780059441 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
Current Respiratory Medicine Reviews The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets A Review on Multi-organ Cancer Detection Using Advanced Machine Learning Techniques
Current Medical Imaging Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Drug Discovery: Structure, Function and Novel Strategy – Part-3
Current Topics in Medicinal Chemistry Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Anti-Cancer Agents in Medicinal Chemistry The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1)
Anti-Cancer Agents in Medicinal Chemistry The Global Component-Target Network in Panax Ginseng C
Letters in Drug Design & Discovery Aberrant DNA Methylation and Prostate Cancer
Current Genomics Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure
Anti-Cancer Agents in Medicinal Chemistry The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment
Clinical Cancer Drugs Impaired Expression and Function of Cancer-Related Enzymes by Anthocyans: An Update
Current Enzyme Inhibition MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine